Skip to main content

Table 4 Average annual percentage of change according to age and tumor subtype from 2011 to 2018 (CI 95%)

From: Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?

 

Triple negative

HER2 amplified

Luminal

 < 40 years

 + 1,4% (–8,2; + 11,0)

 + 6,8% (–1,8; + 15,4)

–0,2% (–5,7; + 5,3)

40–49 years

–4,8% (–12,4; + 2,8)

 + 7,4% (+ 1,1; + 13,7)

–0,1% (–2,8; + 2,5)

50–70 years

–1,3% (–6,1; + 3,4)

 + 3,4% (–0,2; + 7,1)

–0,7% (–2,1; + 0,8)

 ≥ 75 years

 + 4,0% (–5,1; + 13,2)

 + 12,7% (+ 5,2; + 20,2)

 + 1,1% (–1,3; + 3,5)

All age

–0,8% (–4,2; + 2,6)

 + 6,0% (+ 3,2; + 8,7)

–0,1% (–1,2; + 1,0)